ASSOCIATION OF GSTM1 AND GSTT1 NULL GENOTYPES WITH RISK OF NON-HODGKIN MALIGNANT LYMPHOMA
Abstract
The genotypes of glutathione S-transferases M1 and T1 ( GSTM1 0/0 and GSTT1 0/0 ) lead to a decrease in gene expression and a significant decrease in enzymatic activity, and can mediate a susceptibility to non-Hodgkin malignant lymphomas (NHL).Aim: to determine the role of the “” genotypes of glutathione-S-transferases M1 and T1 in creating a risk of developingdiffuse B-large cell, diffuse B-small cell (B-CLL phenotype) lymphomas and follicular lymphoma (grade 1 and 2).Methods. 88 patients (42 men and 46 women; average age 52,6±12,5 years) with a diagnosis of NHL were examined,of which 56 people (63,6%) were verified aggressive NHL - diffuse B-large cell lymphoma, immunoblastic variant, in 32patients, indolent NHCL: diffuse B-small cell lymphoma (B-CLL phenotype) - 17 (19,3%) patients, and follicular lymphomagrade 1 and grade 2 - 15 (17,1%) patients. The control group consisted of 177 residents of Novosibirsk, the average age was31,0±12,02 years. The deletions in the GSTM1 and GSTT1 genes were detected by the method of real-time polymerase chainreaction (Real-time PCR) with intercalating fluorescent dye SYBR GreenI and analysis of melting curves.Results. In the present study we investigated the connection with risks of development of individual variants of NHL:diffuse B-large cell lymphoma, diffuse B-small cell (B-CLL) lymphoma and follicular lymphoma grade 1 and grade 2. Itwas revealed the association of GSTM1 0/0 with an increased risk of follicular lymphoma (OR = 3.06, C.I. [1.01-9.32], p<0.039).Conclusion. This data indicate that the xenobiotic metabolizing gene GSTM1 and GSTT1 may play a role in thepathogenesis of certain variants of NHL.
References
2. Воропаева Е.Н., Поспелова Т.И., Воевода М.И., Максимов В.Н. Результаты комплексного анализа статуса гена TP53 у больных диффузной В-крупноклеточной лимфомой // Гематология и трансфузиология. 2016. Т. 61. № 3. С.138-143.
3. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с.
4. Корчагина Р.П., Осипова Л.П., Вавилова Н.А. и др. Полиморфизм генов биотрансформации ксенобиотиков GSTM1, GSTT1, CYP2D6, вероятных маркеров риска онкологических заболеваний, в популяциях коренных этносов и русских северной Сибири // Вавиловский журнал генетики и селекции. 2011. Т. 15. №3. С.448-461.
5. Поддубная И.В., Савченко В.Г. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. М.: Издательство ООО «Буки-Веди», 2016. 324 с.
6. Agodi A., Barchitta M., Cipresso R., Marzagalli R., et al. Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in sicily // Int. J. Gynecol. Cancer. 2010. Vol. 20. №1. P.141-146.
7. Avti P.K., Vaiphei K., Pathak C.M., Khanduja K.L. Involvement of various molecular events in cellular injury induced by smokeless tobacco // Chem. Res. Toxicol. 2010. Vol. 2. №7. P.1163-1174.
8. Bellido M., Capello D., Altés A., et al. Bcl-6 p53 mutations in lymphomas carrying the bcl-2 rearrangement // Haematologica. 2002. Vol. 87. №9. P.908-917.
9. Bin Q., Luo J. Role of polymorphisms of GSTM1, GSTT1 and GSTP1 Ile105Val in Hodgkin and non-Hodgkin lymphoma risk: a Human Genome Epidemiology (HuGE) review // Leuk Lymphoma. 2013. Vol. 54. №1. P.14-20.
10. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2018. Vol. 68. №6. P.394-424.
11. Chiu B.C. , Hou N. Epidemiology and etiology of NonРodgkin lymphoma // Cancer Treat Res. 2015. Vol. 165. P.394-424.
12. De Oliveria A.L., et al. Chemotherapy and mechanisms of resistance in Breast Cancer // Neoadjuvant Chemotherapy – Current Applications in Clinical Practice. 2012. URL: https://www.researchgate.net/publication/221923640
13. Ferlay J., Colombet M., et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 // Eur J Cancer. 2018. Vol. 103. P.356-387.
14. Hollman A., Tchounwou P., Huang H.C. e association between gene-environment interactions and diseases involving the human GST superfamily with SNP variants // Int J Environ Res Public Health. 2016. Vol. 13. №4. P.379.
15. Li M., Zheng M., Chen H., Yu H. Eects of GST variants on the risk odds of hematological malignancy: A meta-analysis // J Cell Biochem. 2018. P.1-11.
16. Mannetje A., De Roos A.J., Boetta P., et al. Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium // Environ Health Perspect. 2016. Vol. 124. №4. P.396-405.
17. Megias-Vericat J.E., Martinez-Cuadron D., Herrero M.J., et al. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia // Curr Drug Metab. 2018. Vol. 19. №1. P.55-74.
18. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019 // CA Cancer J Clin. 2019. Vol. 69. №1. P.7-34.
19. Singh S. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death // Cancer Chem other Pharmacol. 2015. Vol. 75. P.1-15.
20. Strange R.C., Spiteri M.A., Ramachandran S., et al. Glutathione-S-transferase family of enzymes // Mutat Res. 2001. Vol. 482. №1-2. P.21-26.
21. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classication of Tumours of Haematopoietic and Lymphoid Tissues // (Revised 4th edition). IARC: Lyon 2017. URL: https://www.ncbi.nlm.nih.gov/nlmcatalog/101477951
22. Wang J., Wu D., Sun A. Eects of GST null genotypes on individual susceptibility to leukemia: A meta-analysis // Exp Mol Pathol. 2019. Vol. 108. P.137-142.
23. Wani M.A., Zhu Q., El-Mahdy M., et al. Enhanced sensitivity to anti-benzo(a)pyrene-diol-epoxide DNA damage correlates with decreased global genomic repair attributable to abrogated p53 function in human cells // Cancer Res. 2000. Vol. 60. №8. P.2273-2280.
24. Wu B., Dong D. Human cytosolic glutathione transferases: structure, function, and drug discovery // Trends Pharmacol Sci. 2012. Vol. 33. №12. P.656-668.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
